Virtual Event: The ASH Recap, Live!
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
Category: ASH21
STAT+: More potent version of Global Blood sickle-cell drug improves hemoglobin response in small study
Global Blood Therapeutics said Monday that an experimental treatment for sickle cell disease nearly doubled…
STAT+: J&J’s new CAR-T therapy shows long-term success, data show
By the time patients with multiple myeloma have gone through four or five different therapies,…
STAT+: Mutations tied to blood cancers and other diseases may surprisingly protect against Alzheimer’s
ATLANTA — When key mutations strike bone marrow stem cells, known as hematopoietic stem cells,…
STAT+: Roche two-armed antibody posts strong tumor responses in lymphoma study, rivaling CAR-T therapy
An off-the-shelf bispecific antibody developed by Roche induced high and durable response rates in patients…
STAT+: Patients with rare blood disorder benefit from Bluebird gene therapy while denied access in Europe
People with severe beta-thalassemia who live in Europe have been denied access to Bluebird Bio’s…
STAT+: Gilead, Bristol jaw over the superiority of rival CAR-T treatments for blood cancer
Competing, bespoke CAR-T cell therapies from Gilead Sciences and Bristol Myers Squibb have each demonstrated…